Swiss pharma company Novartis has reached an agreement with Pfizer and BioNTech to provide manufacturing capacity for their COVID-19 vaccine.
Novartis will aim to begin production of the vaccines in the second quarter of 2021, with plans to commence manufacturing at its site in Stein, Switzerland.
“Novartis has been mobilising on multiple fronts to support the global pandemic response,” said Steffen Lang, head of Novartis Technical Operations.
“As a company reimagining medicine with advanced therapy platforms, we are committed to leverage our manufacturing capabilities to help support the supply of COVID-19 vaccines and therapeutics around the world. We expect this to be the first of a number of such agreements,” he added.
n a different agreement, German pharma company Bayer has signed a manufacturing agreement with CureVac to bolster production of CureVac’s investigational COVID-19 vaccine.
Bayer is already supporting the development, supply and key territory operations of CureVac’s vaccine candidate.
Stefan Oelrich, head of Bayer’s pharmaceutical division, said that the company expects to produce 161 million doses of CureVac’s vaccine in 2022.
http://www.pmlive.com/pharma_news/novartis,_bayer_announce_separate_agreements_to_bolster_covid-19_vaccine_manufacturing_1362454
https://www.curevac.com/en/become-part-of-the-rna-people/